Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of SPD465 in Adults With ADHD
NCT00150579Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2005
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of SHP465 mixed amphetamine salts in attention deficit hyperactivity disorder (ADHD), sponsored by Takeda. Started Jan 2005; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00150579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00150579.